The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group - PubMed (original) (raw)

Clinical Trial

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group

M A Raskind et al. J Clin Psychiatry. 1999 May.

Abstract

Background: The objective of this study was to evaluate the efficacy and safety of metrifonate, a long-acting acetylcholinesterase inhibitor, in patients clinically diagnosed with probable Alzheimer's disease of mild-to-moderate severity.

Method: This was a prospective, multicenter, 26-week, double-blind, parallel group study. The 264 randomized patients met diagnostic criteria of the National Institute of Neurological and Communicative Diseases and Stroke and the Alzheimer's Disease and Related Disorders Association for probable Alzheimer's disease. Patients had Mini-Mental State Examination (MMSE) scores of 10-26 and ischemic scores (Rosen modification) of <4. Metrifonate-treated patients received a single 50-mg dose once daily. The efficacy of metrifonate was investigated with respect to 3 symptom domains. Cognitive performance was analyzed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the MMSE. Psychiatric and behavioral disturbances were analyzed using the Neuropsychiatric Inventory (NPI) and the ADAS-Noncognitive subscale (ADAS-Noncog). The ability to perform instrumental and basic activities of daily living was evaluated using the Disability Assessment for Dementia (DAD) scale. Additionally, global state was assessed using the Clinician Interview-Based Impression of Change with Caregiver Input (CIBIC-Plus) scale.

Results: After 26 weeks of metrifonate therapy, a statistically significant benefit of metrifonate was observed in the cognitive performance of Alzheimer's disease patients (ADAS-Cog, t = 2.55, df = 237, p = .012; MMSE, t = 4.60, df = 237, p = .0001). Metrifonate also significantly attenuated the deterioration in activities of daily living of the patients (DAD total score, t = -2.11, df = 233, p = .036) and relieved patients' psychiatric and behavioral disturbances (NPI total score, t = 2.51, df = 233, p = .013). In addition, metrifonate significantly improved the scores for the global state of the patients (CIBIC-Plus, t = 2.07, df = 232, p = .039). Metrifonate was well tolerated; adverse events were predominantly mild in intensity, and no hepatotoxicity was observed.

Conclusion: In this study, metrifonate was safe and well tolerated. It benefited the cognitive decline, psychiatric and behavioral disturbances, impaired ability to perform instrumental and basic activities of daily living, and global state of patients diagnosed with mild-to-moderate Alzheimer's disease.

PubMed Disclaimer

Comment in

ACP J Club. 1999 Nov-Dec;131(3):72
Metrifonate for Alzheimer's disease patients.
Schneider LS. Schneider LS. J Clin Psychiatry. 2000 Mar;61(3):218-9. doi: 10.4088/jcp.v61n0312d. J Clin Psychiatry. 2000. PMID: 10817111 No abstract available.

Cited by

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Rockwood K, et al. J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95. doi: 10.1136/jnnp.71.5.589. J Neurol Neurosurg Psychiatry. 2001. PMID: 11606667 Free PMC article. Clinical Trial.
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR, Peters D, Sparks RG. Mirza NR, et al. CNS Drug Rev. 2003 Summer;9(2):159-86. doi: 10.1111/j.1527-3458.2003.tb00247.x. CNS Drug Rev. 2003. PMID: 12847557 Free PMC article. Review.
Pharmacotheraphy for Alzheimer's disease.
Knopman D. Knopman D. Curr Neurol Neurosci Rep. 2001 Sep;1(5):428-34. doi: 10.1007/s11910-001-0102-y. Curr Neurol Neurosci Rep. 2001. PMID: 11898553 Review.
Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
Giacobini E. Giacobini E. CNS Drugs. 2001;15(2):85-91. doi: 10.2165/00023210-200115020-00001. CNS Drugs. 2001. PMID: 11460892 Review.
Pharmacological interventions for apathy in Alzheimer's disease.
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Ruthirakuhan MT, et al. Cochrane Database Syst Rev. 2018 May 4;5(5):CD012197. doi: 10.1002/14651858.CD012197.pub2. Cochrane Database Syst Rev. 2018. PMID: 29727467 Free PMC article. Review.

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group - PubMed (original) (raw)